RecruitingNCT06578702ETRIVIEUpdated Aug 29, 2024

Evaluation of Intermittent Triple Therapies in Real Life

An observational study in HIV Infections, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-29.

Sponsored by University Hospital, Strasbourg, France · Observational

From the registry’s dates

Primary completion was expected by Feb 2025, 1 year 8 months ago, but the record still lists the study as recruiting.
Started Feb 2024; still recruiting 2 years 7 months later.

Study type: Observational
Model: Case-only
Time perspective: Retrospective
Enrollment: 200
Ages: 18 Years and older
Sex: All

Study summary

The strategy of intermittent triple therapy for people living with HIV was validated in France following the randomized clinical trial QUATUOR. There is little data in real life, as shown in the meta-analysis of Parienti JJ et al.

Currently this strategy is proposed by some teams in France, but is not recommended internationally.

The research hypothesis is that intermittent treatment is an effective and safe option in a therapeutic lightening strategy in people living with HIV People living with HIV adults followed in Strasbourg who have benefited from intermittent treatment The expected results will consist of an improvement in knowledge on the efficacy and tolerance of this therapeutic strategy.

Conditions studied

HIV Infections

Browse trials for

HIV Infections 4,258

Keywords

HIV Infections
Intermittent Triple Therapy

In context

HIV Infections

4,258 studies on the registry are indexed under HIV Infections; 240 are open to participants now.

This study's planned enrollment of 200 is close to the median of 200 across 713 observational studies indexed under HIV Infections.

Browse HIV Infections studies →

Lead sponsor

University Hospital, Strasbourg, France is the lead sponsor of 966 studies on the registry; 342 are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years and older
Sexes eligible: All
Accepts healthy volunteers: No
Sampling method: Non-probability sample

Study population

Adult subject (≥ 18 years old) living with HIV monitored at the Trait d'Union/Infectious Diseases department in Strasbourg and having benefited from intermittent triple therapy

Inclusion criteria

Adult subject (≥ 18 years old)
Living with HIV monitored at the Trait d'Union/Infectious Diseases department in Strasbourg
Having benefited from intermittent triple therapy between 01/01/2017 and 31/01/2024

Exclusion criteria

Exclusion criteria:

Subject (and/or their legal representative if applicable) having expressed their opposition to the reuse of their data for scientific research purposes.

Study design

Observational model: Case-only
Time perspective: Retrospective
Enrollment: 200 participants (estimated)
Patient registry: No

What researchers measure

Primary outcomes

Evaluation of HIV viral load
Time frame: 48 weeks after reduction of the HIV viral load

Study locations

1 of 1 sites recruiting

Service Le Trait d'Union - CHU de Strasbourg - France
Strasbourg, 67091, France
- Axel URSENBACH, MD · Contact · axel.ursenbach@chru-strasbourg.fr · 33 3 69 55 13 52
- Axel URSENBACH, MD · Principal investigator
- David Rey, MD · Sub investigator
- Paul Klee, MD · Sub investigator
- Céline Melouno, MD · Sub investigator
- Baptiste Hoellinger, MD · Sub investigator
- Thomas Lemmet, MD · Sub investigator
Recruiting

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Aug 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT06578702
Lead sponsor: University Hospital, Strasbourg, France
Responsible party: Sponsor
First posted: Aug 29, 2024
Start date: Feb 21, 2024
Primary completion: Feb 2025 (estimated)
Completion: Feb 21, 2025 (estimated)
Last update: Aug 29, 2024

Study contacts

Axel URSENBACH, MD

Contact

axel.ursenbach@chru-strasbourg.fr

33 3 69 55 13 52

Oversight

Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

HIV Infections→

Other studies from this sponsor

University Hospital, Strasbourg, France

Start the discussion